RxDoctor Payments Data

Willem Sorgeloos, DPM

Podiatrist · Hattiesburg, MSNPI 1861929648

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Zimmer Biomet accounts for 68.9% of it on its own, with 2 other manufacturers making up the rest. 2022 is the largest year on record at $99, 6.1 times the $16 reported in 2020. That places this record below the midpoint for podiatrist clinicians in MS, where the typical reported total is $566.

$144in general payments, 2019–2025

Across 4 payments — averaging $36.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$99
  • Smith+Nephew$29
  • Stimwave Technologies Incorporated$16

What the payments were for

  • Food & beverage$144100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$144 in reported general payments places this provider in the 20th percentile of 28 podiatrist providers in Mississippi.

See all podiatrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$409,582
Medicare patients
694
Services billed
6,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CiclopiroxCiclopirox Olamine333$7,938
SantylCollagenase Clostridium Hist.20$7,818
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip87$2,414
Ammonium Lactate94$2,169
Ciclopirox107$2,161
Gabapentin329$1,472
Cephalexin286$1,453
Pregabalin18$407
Terbinafine Hcl13$269
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim81$261
Ibuprofen46$173
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen39$168
Meloxicam69$159
Diclofenac Sodium14$123
Ciprofloxacin Hcl16$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$29$7,81820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 28 podiatrist providers in Mississippi.

Other podiatrist in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →